Repare Therapeutics Announces US$82.5 Million Series B Financing

Sep 4, 2019 09:00 UTC CAMBRIDGE, Mass. & MONTREAL–(Business Wire)–Repare Therapeutics, a precision oncology company targeting specific vulnerabilities of tumors in genetically defined patient populations, announced today the completion of a US$82.5 million Series B financing. Cowen Healthcare Investments led the financing and was joined by new investors OrbiMed, […] Click here to view original[…]

Could even more cancer patients benefit from PARP inhibitors?

Childhood leukemia survivors may be at higher risk for infections

Childhood leukemia survivors demonstrated a higher long-term risk for infections after treatment completion than the general population, according to a study published in the Journal of Clinical Oncology. “Children who have completed leukemia therapy may remain at higher risk [for] infections, as prior laboratory studies have shown persistent immune […] Click here to view original[…]

AstraZeneca's Tagrisso helps lung cancer patients live longer- study (Aug. 9)

AstraZeneca’s Tagrisso helps lung cancer patients live longer- study (Aug. 9)

Reuters Aug 9 (Reuters) – AstraZeneca Plc said on Friday a late-stage study showed its top-selling drug, Tagrisso, had significantly helped patients with a type of lung cancer live longer. The British drugmaker announced overall positive survival results from the study in patients with epidermal growth factor receptor-mutated metastatic […] Click here to view original[…]